Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Gin Hwa Biotech's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2025 was 6.00%.
As of today (2026-07-22), Gin Hwa Biotech's WACC % is 9.43%. Gin Hwa Biotech's ROIC % is 10.13% (calculated using TTM income statement data).
Gin Hwa Biotech generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.
Gin Hwa Biotech (ROCO:7806) ROIC % Explanation
ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.
There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.
Why is ROIC % important?
Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Gin Hwa Biotech's WACC % is 9.43%. Gin Hwa Biotech's ROIC % is 10.13% (calculated using TTM income statement data).
Gin Hwa Biotech generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.
Be Aware
Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Gin Hwa Biotech ROIC % Related Terms
Gin Hwa Biotech ROIC % Historical Data
* Premium members only.
The historical data trend for Gin Hwa Biotech's ROIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Gin Hwa Biotech's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gin Hwa Biotech ROIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gin Hwa Biotech's ROIC % distribution charts can be found below:
* The bar in red indicates where Gin Hwa Biotech's ROIC % falls into.
Note:
The Operating Income data used here is two times the semi-annual (Dec. 2025) data.
The tax rate is limited to between 0% and 100%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gin Hwa Biotech (ROCO:7806) has a ROIC % of 6.00% as of Dec. 2025. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Gin Hwa Biotech and its competitors.
Is Gin Hwa Biotech's ROIC % too high?
Gin Hwa Biotech's current ROIC % is 6.00%. Overall, Gin Hwa Biotech has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Gin Hwa Biotech's ROIC % compare to VRTX and REGN?
Gin Hwa Biotech's ROIC % of 6.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Biotechnology company?
A good ROIC % depends on the Biotechnology industry context. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Gin Hwa Biotech and its competitors. Gin Hwa Biotech's current ROIC % is 6.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gin Hwa Biotech stock overvalued right now?
Gin Hwa Biotech (ROCO:7806) has a current ROIC % of 6.00%. The current ROIC % is 6.00%. Gin Hwa Biotech's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For Gin Hwa Biotech (ROCO:7806), the current ROIC % is 6.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Gin Hwa Biotech Inc is engaged in developing completely original products to achieve every vision. Its Services and technology are Product Development, OEM Service, Core Technology, R & D Center, Professional Production, and Others.
22GF Score
Get the complete analysis for ROCO:7806
ROIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7806 has been successfully added to your 
